Wednesday, August 29, 2012

Is Chiropractic for Low-Back Pain Effective?

Back PainLower back pain (LBP) is a common and costly musculoskeletal problem, affecting about 80% of all persons at some time in their lives. Many people with this condition seek the care of a chiropractor who may utilize a range of interventions such as spinal manipulation, massage, electrotherapy, mechanical devices, exercise, orthotics, and others. A recent large study found that chiropractic was effective in treating both acute and chronic LBP; however, there were considerable limitations of this study that question its external validity.

For this prospective cohort study adult patients with LBP who had not received chiropractic or manual therapy in the prior 3 months were recruited from multiple chiropractic practices in Switzerland [Peterson et al. 2012]. Patients were excluded if they had specific lumbar spine pathologies that are relative contraindications to chiropractic manipulative therapy, including tumors, infection, inflammatory spondyloarthropathies, fractures, severe osteoporosis, and Paget’s disease (bone deformities).

The purpose of the study was to evaluate outcomes in routine practice, so the 44 chiropractors volunteering to participate were allowed to administer their typical treatment methods (such as spinal manipulation, soft tissue mobilization, or others). Patients completed a numerical pain rating scale (NRS) and the Oswestry disability questionnaire at baseline immediately before treatment, and at 1 week, 1 month, and 3 months after the start of treatment. Subjects also self-reported perceived improvement on a Patient Global Impression of Change (PGIC) scale.

Monday, August 27, 2012

Introducing “Understanding UDT in Pain Care”

Understanding UDTPart 1: Clinical Complexities and Medical Mandates
By Stewart B. Leavitt, MA, PhD and Gary M. Reisfield, MD

Urine drug testing, or UDT, is one of the most controversial, yet potentially important, components of effective pain management and pharmacovigilance. However, when UDT is motivated by fear and coercion, rather than diagnostic and therapeutic objectives, it can be offensive or intimidating to patients and misunderstood or misused by practitioners. Yet, UDT is becoming an increasingly accepted and emerging standard of practice that, if done at all, should be done properly. For this, a much better understanding of UDT in clinical pain care is needed.

Successful treatment of an underlying pain disorder is dependent on patient self-reports. But, it is critical that clinicians have objective means of monitoring patients’ adherence to prescribed pharmacotherapies for pain and, considering its utility, accuracy, and ease of administration, UDT is an objective measure of choice. Exploring the rationales, applications, benefits, and limitations of UDT for better pain care, while bridging current knowledge gaps, is the mission of this special Pain-Topics UPDATES series.

Thursday, August 23, 2012

When is Rx-Opioid “Addiction” Something Else?

Addiction2The onerous specter of addiction resulting from the long-term administration of opioid analgesics in patients with chronic pain has often been raised in reports from various sources and in sensational news stories. In actuality, “addiction” is probably one of the most overused and misunderstood terms in medicine, and the absolute risks of addiction newly emerging during analgesic therapy are still uncertain. Now, a recent article suggests that addiction might be better understood in patients receiving opioid therapy as a complex persistent opioid dependence; however, this may be an oversimplification.

Illicit opioids, like heroin, are well-known to produce an addiction disorder in persons who repeatedly abuse the substances for their mood-altering effects. At the same time, medicinal opioids are powerful analgesics that, when properly prescribed and used, can provide vital relief of physical pain and emotional suffering. Within the medical community there is ongoing concern about how opioid analgesics can be safely prescribed long-term for treating chronic pain without the unintended consequence of new (de novo) addiction arising as a direct result of the therapy (iatrogenic).

Wednesday, August 22, 2012

Pain Plagues Patients with Type 2 Diabetes

About 4 in 10 adults with type 2 diabetes report acute and chronic pain, and close to one quarter report neuropathy, fatigue, depression, and sleep disturbance, according to a study of more than 13,000 adults conducted by researchers in California. Patients in the study reported significant pain and non-pain symptoms across the entire course of the disease, among all age groups, with prevalence increasing as people neared the end of their lives.

Writing in an early online edition of the Journal of General Internal Medicine the researchers — from the San Francisco VA Medical Center, the University of California, San Francisco, and the Kaiser Permanente Division of Research in Oakland, CA — report on the largest observational study to assess a full range of pain and non-pain symptoms among patients with type 2 diabetes, at various time points and by age, and the first to characterize the kinds of symptoms that patients experience [Sudore et al. 2012, ref below]. Here are study details:

Monday, August 20, 2012

A “PROMPT” Response to the PROP Opioid Petition

By Guest Author Jeffrey Fudin, BS, PharmD, DAAPM, FCCP

After reading the petition dated July 25, 2012 to the FDA from PROP (Physicians for Responsible Opioid Prescribing) requesting opioid labeling changes [PDF here], Dr. Fudin posted his own thoughts in rebuttal on August 5, 2012 at his PainDr.com blog [PDF here]. Going further, he founded a new organization of healthcare professionals, called PROMPT, to help clarify issues regarding effective and safe opioid prescribing in patients with chronic noncancer pain. Following, is his update on these activities. [Note: all links in this article open in a separate browser window, so you will not lose your place on this page.]

My first reactions to the PROP Petition to the FDA were disbelief; a nagging requisite for swift response, but from a multidisciplinary group of healthcare providers. As a result, “PROMPT” (Professionals for Rational Opioid Monitoring & PharmacoTherapeutics) was born [info here]. Unlike PROP (Physicians for Responsible Opioid Prescribing [website here]), the intent was to include a diversity of healthcare professionals (after all, it takes a whole neighborhood of professionals to adequately address complex chronic pain) and not to assume that prescribers are otherwise irresponsible if they do not follow the PROP platform.

Friday, August 17, 2012

HCV Screening Urged for All Persons Aged 47-67

HCV AwareThe U.S. CDC (Centers for Disease Control and Prevention) has issued a strong recommendation that, even without known risk factors, all Americans born between 1945 and 1965 should have a one-time screening for the hepatitis C virus (HCV). This could be of special importance for persons in that age range, currently 47 to 67 years, with chronic pain conditions who may have received transfusions, injections, acupuncture, or other invasive medical procedures in the past, but were never specifically tested for HCV.

The recommendations, published early online in the Annals of Internal Medicine, also stress that all persons identified as infected with HCV should receive a brief alcohol screening and intervention and be referred to appropriate care and treatment services for HCV and related conditions [Smith et al. 2012]. Nearly 4 million persons in the United States are infected with HCV, a virus that can cause inflammation and permanent liver damage.

Thursday, August 16, 2012

Headache? Drink Lots of Water, Researchers Say.

Headache WaterFor persons suffering numerous headaches each month, researchers found that drinking an additional 6 glasses of water each day could ease the pain and improve quality of life. However, while news media thought this was a terrific idea, there were some limitations of this research that might temper enthusiasm for the approach.

Writing in the journal Family Practice, researchers from the Netherlands report a randomized controlled trial in a primary care setting on the effects of increased water intake in patients with recurrent headaches. There were 50 patients randomized to the control group and 52 patients to the water intervention group. Patients were included if they had at least 2 episodes of moderately intense headache or at least 5 milder episodes per month and a total fluid intake of less than 2.5 Liters per day (about 85 ounces).

Wednesday, August 15, 2012

Kinesio Tape for Pain? The Science is Sticky.

Kinesio TapeAnyone who watched even snippets of the recent Olympic Games on TV probably noticed the intriguing, brightly-colored strips of tape adorning shoulders, arms, legs, abs, or other anatomy of many athletes. Apparently, the stretchy cotton bands called Kinesio® Tape are liberally applied when and wherever performance-robbing musculoskeletal pain strikes. But, is this product a clever marketing ploy, a sporty fashion statement, a colorful placebo, or the real deal? And, is this something that non-athletes with pain should look into?

According to news articles [here] and [here], and information at the Kinesio website [here], the tape was designed several decades ago by Kenzo Kase, a Japanese chiropractor and acupuncturist, to support injured muscles, increase range of motion, and decrease pain. Ostensibly, Kase considered rigid athletic tapes inadequate and believed his patients needed something with “a texture and elasticity very close to living human tissue.”

Friday, August 10, 2012

Iced Tea May Contribute to Painful Kidney Stones

IcedTeaPeople who have a tendency to form kidney stones, or are concerned about developing the painful disorder, should skip that extra glass of iced tea this summer. According to John Milner, MD, a urologist at Loyola University Medical Center, Maywood, IL, iced tea contains high concentrations of oxalate, one of the key chemicals that lead to the formation of kidney stones — a fairly common disorder that affects about 1 in every 10 persons in the United States.

“For people who have a tendency to form the most common type of kidney stones, iced tea is one of the worst things to drink,” Dr. Milner said in a news release on August 2, 2012 [here]. He further notes that a frequent cause of kidney stones is not drinking enough fluids and, during the summer, people can become dehydrated from sweating. Dehydration, combined with increased iced tea consumption, raises the risk of kidney stones in some persons, especially in those already at risk.

Wednesday, August 8, 2012

Kolodny Responds to UPDATES on PROP Petition

FeedbackAs discussed in recent Pain-Topics UPDATES [here] and [here], on July 25, 2012, Physicians for Responsible Opioid Prescribing, or PROP, submitted a Citizen Petition to the United States Food and Drug Administration (FDA) requesting labeling changes for all opioid analgesics when it comes to their prescription for noncancer pain. In fair balance, we extended to Andrew Kolodny, MD — president of PROP and a principal signer of the Petition — an invitation to submit for publication a rebuttal article commenting on our UPDATES and/or further presenting his group’s perspectives.

Dr. Kolodny promptly responded and we thank him for that. Following, is the text of an e-mail received from him this afternoon (8/8/2012, reprinted with permission), as well as the press release that he requested we reprint.

Opioids on Trial, But Where’s the Evidence?

Editor's NotebookA recent Citizen Petition to the United States Food and Drug Administration (FDA) by Physicians for Responsible Opioid Prescribing, or PROP, requests labeling changes for all opioid analgesics when it comes to their prescription for noncancer pain. The changes would limit the dose, impose time limits, and restrict opioid use for only severe pain.

The Petition raises some important questions about the safety and efficacy of opioid analgesics as they are currently FDA-approved and prescribed. And, the urgency of an investigation was heightened by the fact that a Congressional committee has joined the petitioners in demanding action from the FDA. But, a critical question is whether there is sufficient evidence of reasonable quality for the FDA to act on the Petition at this time.

Tuesday, August 7, 2012

What is Noncancer vs Cancer Pain?

By guest author Lynn Webster, MD, at the LifeSource Blog
The following UPDATE is from an article by Dr. Webster titled “Rethinking the Hierarchy,” in which he discusses differences between noncancer and cancer pain — most especially, the lack of true differences — when it comes to treatment with opioid analgesics for chronic pain. It is reprinted with permission from a posting on August 3, 2012 at the LifeSource Blog [here].

For a riveting read, see “The Emperor of all Maladies: A Biography of Cancer,” by Siddhartha Mukherjee. The book chronicles the history of humankind’s most feared disease, including a multitude of treatment failures. The word cancer conjures a picture of death to many people. Not only was cancer nearly always terminal, but dying in pain was expected, the norm.

Thursday, August 2, 2012

Group Petitions FDA to Change Opioid Label

Guest AuthorBy guest author, Bob Twillman, PhD, FAPM

On July 25 2012, Physicians for Responsible Opioid Prescribing (PROP) submitted a petition to the US Food and Drug Administration (FDA) on behalf of its members, several other individual healthcare provider signatories, and the advocacy group Public Citizen, requesting changes to the currently approved label for opioid analgesics. [The petition document is available here.]

I have a number of concerns about this petition and about the quality of the stated scientific basis for it. I believe the changes requested could severely impede the provision of the kind of high-quality, individualized, integrated biopsychosocial care for chronic pain called for by the 2011 Institute of Medicine report on chronic pain.

In their letter, the petitioners explain that the current FDA-approved indication for nearly all opioid analgesics on the market is for treatment of “moderate to severe pain,” with the addition of “when a continuous, around-the-clock analgesic is needed for an extended period of time” for extended-release opioids. They assert that many clinicians mistakenly believe that this indication means that long-term opioid therapy is appropriate for chronic non-cancer pain, leading to overprescribing and harm to patients.

Wednesday, August 1, 2012

Aug 2012 – Pain Product Announcements & Warnings

AnnouncementsFeatured Items: delayed-release prednisone (Rayos) approved for rheumatoid arthritis and 5 additional indications; generic pregabalin approved; FDA REMS approval for long-acting and extended-release opioids; makers of unapproved oxycodone products warned to stop; defective Hospira injectable vials recalled. — All brand names are trademarks of their respective manufacturers. Compiled by Winnie Dawson, MA, RN, BSN.

Delayed-Release Prednisone (Rayos®) - Approved for RA and Added Indications
U.S. Food and Drug Administration (FDA) officials gave Horizon Pharma a July 2012 approval to market Rayos delayed-release tablets for the treatment of rheumatoid arthritis (RA), polymyalgia rheumatica (PMR), psoriatic arthritis (PsA), ankylosing spondylitis (AS), asthma, and chronic obstructive pulmonary disease (COPD). Rayos — a proprietary low-dose delayed-release formulation of the anti-inflammatory drug prednisone — prevents the release of signaling molecules that cause inflammation in the body.